Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24884532)

1.

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, Minev B, Koropatnick J, Marincola FM, Riordan NH.

J Transl Med. 2014 May 13;12:127. doi: 10.1186/1479-5876-12-127. Review.

3.

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Ichim TE, Minev B, Braciak T, Luna B, Hunninghake R, Mikirova NA, Jackson JA, Gonzalez MJ, Miranda-Massari JR, Alexandrescu DT, Dasanu CA, Bogin V, Ancans J, Stevens RB, Markosian B, Koropatnick J, Chen CS, Riordan NH.

J Transl Med. 2011 Mar 4;9:25. doi: 10.1186/1479-5876-9-25.

4.

Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.

Vaglini M, Belli F, Santinami M, Arienti F, Parmiani G, Persiani L, Santoro N, Grazia Inglese M, D'Elia F, Cascinelli N.

Ann Surg Oncol. 1995 Jan;2(1):61-70.

PMID:
7834457
5.

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al.

J Natl Cancer Inst. 1992 Jun 17;84(12):929-37.

PMID:
1629914
6.

Overview of interleukin-2 as an immunotherapeutic agent.

Chang AE, Rosenberg SA.

Semin Surg Oncol. 1989;5(6):385-90. Review.

PMID:
2688029
7.

New clinical trials with interleukin-2: rationale for regional administration.

Roth AD, Kirkwood JM.

Nat Immun Cell Growth Regul. 1989;8(3):153-64. Review.

PMID:
2674703
8.

Immunotherapy for advanced renal cell cancer.

Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425. Review.

PMID:
15674877
9.

Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2.

Citterio G, Pellegatta F, Lucca GD, Fragasso G, Scaglietti U, Pini D, Fortis C, Tresoldi M, Rugarli C.

Br J Cancer. 1996 Oct;74(8):1297-301.

10.

Rapid cytokine release in cancer patients treated with interleukin-2.

Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS.

J Immunother (1991). 1992 Aug;12(2):123-31.

PMID:
1504053
11.

Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.

Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S93-8.

PMID:
10685667
12.

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Baars JW, Hack CE, Wagstaff J, Eerenberg-Belmer AJ, Wolbink GJ, Thijs LG, Strack van Schijndel RJ, van der Vall HL, Pinedo HM.

Br J Cancer. 1992 Jan;65(1):96-101.

13.
14.

Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.

Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.

Cancer. 1993 Sep 1;72(5):1733-42.

PMID:
8348502
15.

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al.

J Clin Oncol. 1992 Feb;10(2):275-81.

PMID:
1732429
16.

Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis.

Fowler AA 3rd, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S; Medical Respiratory Intensive Care Unit Nursing, Fisher BJ, Natarajan R.

J Transl Med. 2014 Jan 31;12:32. doi: 10.1186/1479-5876-12-32.

17.

Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.

Donskov F.

Dan Med Bull. 2007 Nov;54(4):249-65. Review.

PMID:
18208677
18.

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.

Atzpodien J, Lopez Hänninen E, Kirchner H, Franzke A, Körfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H.

Eur J Cancer. 1995 Jun;31A(6):876-81.

PMID:
7646914
19.

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.

Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB.

J Clin Oncol. 1997 Mar;15(3):1052-62.

PMID:
9060545
20.

Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.

Ridolfi R, Flamini E, Riccobon A, De Paola F, Maltoni R, Gardini A, Ridolfi L, Medri L, Poletti G, Amadori D.

Cancer Immunol Immunother. 1998 Jun;46(4):185-93.

PMID:
9671141
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk